Breaking News: Bioteke's Unveils Cutting-Edge Tumor Marker Rapid Test Kits for AFP And NSE

We are pleased to announce that Bioteke Corporation has recently launched a new breakthrough product in the field of cancer diagnosis - AFP and NSE Rapid Test Kits. 

These detection products use immunochromatography technology and double antibody sandwich method to quickly and accurately detect alpha-fetoprotein (AFP) and neuron-specific enolase (NSE) markers associated with liver cancer and neuroendocrine tumors.

• The AFP rapid test kit is used to detect alpha-fetoprotein in human samples (whole blood, serum, plasma), and is mainly used clinically for auxiliary diagnosis, efficacy and prognosis observation of primary liver cancer.

  

• The NSE rapid test kit is used to detect neuron-specific enolase in human samples (whole blood, serum, plasma), and is mainly used clinically for auxiliary diagnosis of small cell lung cancer (SCLC) and differential diagnosis of non-small cell lung cancer (NSCLC), monitoring of SCLC and neuroblastoma changes, treatment response and monitoring recurrence.

  

The test results can be obtained within 10-15 minutes, helping medical professionals make more informed decisions faster, increasing the possibility of early detection, and helping patients monitor treatment effects.

Bioteke is committed to innovation in the fight against cancer, and the launch of this new rapid test is a reflection of our commitment to excellence and innovative technology.

Learn how Bioteke's rapid tumor marker tests can bring greater precision to your diagnostic process. Stay tuned for more updates on product availability and distribution.

For inquiries, please contact the Bioteke team [zr@bioteke.cn].

-- Bioteke | Leading the future of diagnostic solutions

BioTeke Corporation

www.bioteke.cn